Clinical Trial Search

Primary: Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16…

Primary: Disease-free Survival (Percentage of Participants Alive Without Disease) — 86.4; 82.1; 76.2; 76.9 percentage of participants — p=0.56

Primary: Overall Survival — 17.25; 17.94 months — p=0.5487

Primary: Facial Nerve Recovery — 7; 81.56 Days

Primary: Percent of Subjects Achieving Seroconversion Increased More Than 4-fold Versus Baseline for Antigens: Influenza Virus Type А - H1N1, Influenza Virus Type А - H3N2…

Primary: Percentage of Participants With no Change or a Reduction From Baseline in the Number of Gadolinium Enhancing (GdE) Lesions at Month 12 Using Non-responder Imputation…

Primary: Trough FEV1 on Day 85 — 55.12; -95.78 mL — p=<0.0001

Primary: Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint) — -19.41; -11.73 Unit on a scale — p=<…

Primary: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) — 4.7; 6.3; 39.0; 35.2 Percentage of Participants

Primary: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) — 11; 10 Participants

Primary: Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 — 13.7; 16.2 percentage of…

Primary: Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis — -1.88; -1.68 percentage of HbA1c — p=<0.001

Primary: Overall Correct Initial TASS Outcome, Worst Case Imputation, First Co-Primary Endpoint (Self-Selection Population) — 1085 Participants

Primary: Bayley III Composite Cognitive Score — 80.7; 80.1 score on a scale — p=0.88

Primary: Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale — 219; 188; 197; 119…